Subscribe via RSS- NEWS ARCHIVES
-
2008
2007
2006
2005
2004
Pharma & Bio Ingredients
The company said the study found that the drug, currently called APD125, improved sleep parameters, didn't impair next-day psychomotor skills or memory, and demonstrated an excellent safety and tolerability profile.
"We are pleased to see the favorable Phase 1 clinical data demonstrating that APD125 has the potential to improve sleep maintenance and reduce insomnia symptoms," President and Chief Executive Jack Lief said in a prepared statement. "We believe APD125 merits further evaluation as a novel therapy to promote sleep maintenance, and we look forward to initiating a Phase 2 clinical trial of APD125 in patients with chronic insomnia."
